O

OU Health | Stephenson Cancer Center

Research site
(Unclaimed)
Location
920 Stanton L. Young Boulevard, Suite 1240, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Nivolumab
Pembrolizumab
Avelumab
Paclitaxel
REGN2810
Platinum
Gemcitabine
Palbociclib
Niraparib
Bevacizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

39 of 112 total trials

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Active, not recruiting
HER2-positive Endometrial Cancer
HER2-positive Colorectal Cancer
Drug: BDC-1001
Drug: Nivolumab

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad)...

Enrolling
Solid Tumor
Endometrioid Cancer
Drug: Avutometinib (VS-6766) + defactinib

This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or...

Enrolling
Carcinoma, Small Cell Lung
Drug: RRx-001 + eLOOP Device
Drug: Cisplatin/carboplatin plus etoposide

This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has...

Enrolling
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Drug: BI 765049
Drug: ezabenlimab
Locations recently updated

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of a...

Enrolling
Advanced or Metastatic Colorectal Cancer
Biological: Leucovorin
Biological: Fluorouracil

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: ART0380
Drug: Gemcitabine

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in particip...

Active, not recruiting
Melanoma
Cancer
Biological: Ipilimumab
Other: Placebo

The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and...

Enrolling
Solid Tumors
Drug: Nivolumab
Drug: DF6002

* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advan...

Active, not recruiting
Metastatic Colorectal Cancer
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Cetuximab
Drug: ERAS-007

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients wit...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (...

Enrolling
Solid Tumor
Drug: NDI-101150
Drug: Pembrolizumab
Locations recently updated

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Niraparib
Drug: Prednisone

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who prog...

Active, not recruiting
Gastrointestinal Stromal Tumors
Drug: Sunitinib
Drug: Ripretinib
Locations recently updated

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Enrolling
Urinary Bladder Neoplasms
Drug: Cisplatin
Radiation: Hypo-fractioned radiation therapy

Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the...

Enrolling
B-cell Non-Hodgkin Lymphoma (NHL)
Drug: Odronextamab

This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tole...

Active, not recruiting
Colorectal Adenocarcinoma
Solid Tumor, Adult
Drug: NT219 and ERBITUX® - Dose Escalation
Drug: NT219

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, p...

Enrolling
Advanced Pancreatic Cancer
Drug: Zimberelimab
Drug: Gemcitabine

The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main...

Enrolling
Endometrial Cancer
Gastric Cancer
Drug: TOS-358

The purpose of this research study is to test the safety of avelumab and AVB-S6-500 and see what effects (good and bad) this combination treatment ha...

Active, not recruiting
Urothelial Carcinoma
Drug: AVB-S6-500
Drug: Avelumab

The purpose of this research study is to test the proportion of tumor response to the combination treatment with niraparib and bevacizumab and see wh...

Enrolling
ARID1A Gene Mutation
Recurrent Endometrial Carcinoma
Drug: Niraparib
Drug: Bevacizumab

Trial sponsors

U
Pfizer logo
Regeneron Pharmaceuticals logo
Boehringer Ingelheim logo
Gilead Sciences logo
J
Bristol-Myers Squibb (BMS) logo
EpicentRx logo
ImmunoGen logo
Incyte logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems